IUX24
TopMarketWorldEconomyFinanceTechnologyBusinessPoliticsAnalysis & Opinion

FDA Approves Gilead HIV Pill

The US Food and Drug Administration has approved Gilead Sciences daily combination pill Bixlenvo for treating adults with suppressed HIV. The drug priced at $4595 for a monthly supply aims to simplify complex treatment regimens for patients.

Xurve View
Insights:
Gilead logo is seen in this illustration taken August 5, 2025. REUTERS/Dado Ruvic/Illustration

Gilead Sciences Inc received regulatory clearance in the United States for Bixlenvo, a once-daily combination pill priced at $4,595 per 30-day supply.
IUX24

IUX24 AI-powered financial news and market intelligence. Think and act like smart money.

IFZA Properties, Dubai Silicon Oasis, DSO-IFZA, Dubai, United Arab Emirates

Copyright IUX24 MEDIA - FZCO. All rights reserved.

Powered by AI • Made with precision

IUX24 is an information and analytics platform providing news, market data, analytical tools, and AI-powered features for informational and educational purposes. The Services and information provided do not constitute investment advice, trading signals, or brokerage services. Investing involves risk, and Users should carefully evaluate information before making investment decisions.